Journal of Blood Disorders & Transfusion

Wolfgang Willenbacher

Publications

• Research Article
  Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience
  Author(s): Normann Steiner, Stephanie Riehl, David Nachbaur, Wolfgang Willenbacher, Gunther Gastl and Eberhard GunsiliusNormann Steiner, Stephanie Riehl, David Nachbaur, Wolfgang Willenbacher, Gunther Gastl and Eberhard Gunsilius
  
  Objective: In clinical trials, the combination of bortezomib, thalidomide, and dexamethasone (VTD) has shown excellent results as induction treatment in patients with multiple myeloma. However, “real-life” data in unselected Caucasian patients are lacking. Methods: We retrospectively analyzed 41 patients treated with VTD between 2005 and 2014.  Results: Post induction, the overall response rate was 78%, with ≥very good partial response (≥VGPR) in 54% and near complete/complete responses (nCR/CR) in 17% of the patients  respectively. For patients proceeding to autologous stem cell transplantation (ASCT), post-transplant rates were 96% ≥VGPR and 48% nCR/CR. Median progression free survival (PFS) was 24 months and the estimated 1-year and 2-year overall survival (OS) rates were 95% and 76%, respectively. Subgroup analyses revealed s.. View More»
  DOI: 10.4172/2155-9864.1000296

  Abstract PDF